Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
Anglès
A
A
Bagheri
H
H
Saivin
S
S
Montastruc
J L
JL
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000150:complications*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D000978:Antiparkinson Agents; D064747:Lansoprazole; D001971:Bromocriptine; D009853:Omeprazole